Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01160211 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 369
- Enrollment target
NCT01160211 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 369 participants.
The verdict
NCT01160211, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 369 participants
- Enrollment target
Study Summary
A study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, HER2+ metastatic breast cancer (MBC).
Interventions
- DRUG Trastuzumab
- DRUG Aromatase Inhibitor
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 369 participants |
| Start Date | 2011-05-05 |
| Est. Completion | 2022-06-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01160211
The ClinicalTrials.gov registry entry for NCT01160211 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 369 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab is the first listed.
NCT01160211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01160211 about?
NCT01160211 is a clinical study titled "A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer". A study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, HER2+ metastatic breast cancer (MBC).
What is the current status of trial NCT01160211?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 369 participants. The study started on 2011-05-05. Estimated completion is 2022-06-06.
What interventions are being tested in trial NCT01160211?
The interventions under investigation include: Trastuzumab (DRUG), Aromatase Inhibitor (DRUG), Lapatinib (DRUG).
Who is sponsoring clinical trial NCT01160211?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.